Literature DB >> 2339692

Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT----GGAG).

C P Nogueira1, M C McGuire, C Graeser, C F Bartels, M Arpagaus, A F Van der Spek, H Lightstone, O Lockridge, B N La Du.   

Abstract

A frameshift mutation that causes a silent phenotype for human serum cholinesterase was identified in the DNA of seven individuals of two unrelated families. The mutation, identified using the polymerase chain reaction, causes a shift in the reading frame from Gly 117, where GGT (Gly)----GGAG (Gly+ 1 base) to a new stop codon created at position 129. This alteration is upstream of the active site (Ser 198), and, if any protein were made, it would represent only 22% of the mature enzyme found in normal serum. Results of analysis of the enzymatic activities in serum agreed with the genotypes inferred from the nucleotide sequence. Rocket immunoelectrophoresis using alpha-naphthyl acetate to detect enzymatic activity showed an absence of cross-reactive material, as expected. One additional individual with a silent phenotype did not show the same frameshift mutation. This was not unexpected, since there must be considerable molecular heterogeneity involved in causes for the silent cholinesterase phenotype. This is the first report of a molecular mechanism underlying the silent phenotype for serum cholinesterase. The analytical approach used was similar to the one we recently employed to identify the mutation that causes the atypical cholinesterase variant.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339692      PMCID: PMC1683584     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  43 in total

1.  Suxamethonium in the absence of pseudocholinesterase.

Authors:  S M HART; J V MITCHELL
Journal:  Br J Anaesth       Date:  1962-03       Impact factor: 9.166

2.  On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers.

Authors:  W KALOW; N STARON
Journal:  Can J Biochem Physiol       Date:  1957-12

3.  A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers.

Authors:  W KALOW; K GENEST
Journal:  Can J Biochem Physiol       Date:  1957-06

4.  The familial incidence of low pseudocholinesterase level.

Authors:  H LEHMANN; E RYAN
Journal:  Lancet       Date:  1956-07-21       Impact factor: 79.321

5.  A comparison of optical and manometric methods for the assay of human serum cholinesterase.

Authors:  W KALOW; H A LINDSAY
Journal:  Can J Biochem Physiol       Date:  1955-07

6.  Defective gene in lactic acidosis: abnormal pyruvate dehydrogenase E1 alpha-subunit caused by a frame shift.

Authors:  H Endo; K Hasegawa; K Narisawa; K Tada; Y Kagawa; S Ohta
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

7.  De novo amplification within a "silent" human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides.

Authors:  C A Prody; P Dreyfus; R Zamir; H Zakut; H Soreq
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

8.  A frameshift mutation results in a truncated nonfunctional carboxyl-terminal pro alpha 1(I) propeptide of type I collagen in osteogenesis imperfecta.

Authors:  J F Bateman; S R Lamande; H H Dahl; D Chan; T Mascara; W G Cole
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

9.  Structure of the gene for human butyrylcholinesterase. Evidence for a single copy.

Authors:  M Arpagaus; M Kott; K P Vatsis; C F Bartels; B N La Du; O Lockridge
Journal:  Biochemistry       Date:  1990-01-09       Impact factor: 3.162

10.  Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence.

Authors:  O Miura; S Hirosawa; A Kato; N Aoki
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

View more
  13 in total

Review 1.  Polymerase chain reaction and its potential as a pharmacokinetic tool.

Authors:  M H Heim
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Mechanisms of insertional mutagenesis in human genes causing genetic disease.

Authors:  D N Cooper; M Krawczak
Journal:  Hum Genet       Date:  1991-08       Impact factor: 4.132

3.  DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites.

Authors:  C F Bartels; F S Jensen; O Lockridge; A F van der Spek; H M Rubinstein; T Lubrano; B N La Du
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

4.  Inactivation of the cholinesterase gene by Alu insertion: possible mechanism for human gene transposition.

Authors:  K Muratani; T Hada; Y Yamamoto; T Kaneko; Y Shigeto; T Ohue; J Furuyama; K Higashino
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

5.  Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes.

Authors:  C M Eng; G A Ashley; T S Burgert; A L Enriquez; M D'Souza; R J Desnick
Journal:  Mol Med       Date:  1997-03       Impact factor: 6.354

6.  Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing.

Authors:  B N La Du; C F Bartels; C P Nogueira; M Arpagaus; O Lockridge
Journal:  Cell Mol Neurobiol       Date:  1991-02       Impact factor: 5.046

7.  Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism.

Authors:  C F Bartels; T Zelinski; O Lockridge
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

8.  Prolonged neuromuscular blockade following succinylcholine administration to a patient with a reduced butyrylcholinesterase activity.

Authors:  Ivo F Panhuizen; Marc M J Snoeck; Soledad Levano; Thierry Girard
Journal:  Case Rep Med       Date:  2010-06-17

9.  Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene.

Authors:  S L Primo-Parmo; C F Bartels; B Wiersema; A F van der Spek; J W Innis; B N La Du
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

10.  Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2).

Authors:  Gang Zhou; Gopal K Marathe; Jaana Hartiala; Stanley L Hazen; Hooman Allayee; W H Wilson Tang; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2013-03-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.